Overall rank by patents
#10,988
of 50,000 tracked assignees
USPTO 2015–2025 USPTO PatentsView Foreign Corporation
Liqmeds Worldwide Limited
USPTO PatentsView assignee record - 28 granted patents across 2 technology areas, recorded in grant years 2022–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61K (PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES).
28
Total patents granted
2
CPC technology areas
20.8
Avg claims per patent
-
5-year grant velocity
The verdict
According to USPTO PatentsView, Liqmeds ranks #10,988 of 50,000 tracked US assignees by granted-patent volume, with 28 patents across 2 technology areas.
- #10,988
- of 50,000 US assignees by volume
- Top 15%
- by Innovation Score (49.1/100)
- 20.8
- avg claims per patent
Portfolio overview
Liqmeds Worldwide Limited has been granted 28 US utility patents between 2022 and 2025, placing Liqmeds Worldwide Limited at #10,988 of 50,000 across all assignees tracked by PlainPatent. This portfolio spans 2 distinct Cooperative Patent Classification (CPC) subclasses, averaging 20.8 claims per patent with primary concentration in A61K (PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES). As a Foreign Corporation, Liqmeds Worldwide Limited is one of the more focused assignees in the PatentsView dataset. By volume, Liqmeds sits between Leeo, Inc. (28 patents, rank #10,984) and Matrixed Reality Technology Co., Ltd. (28 patents, rank #10,992) - the closest US assignees by grant volume. The composite Innovation Score of 49.1/100 blends portfolio volume, grant velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Grant cadence records the difference between two grant-year windows. Historical data spans 2022 through 2025, with 28 total grants over that period. Grant timing can lag the related application by years, so this comparison does not establish current R&D spending, strategic intent, or a company’s application activity. The Foreign Corporation classification provides context for the assignee record, not a conclusion about its business strategy.
Claim depth and technology breadth describe this aggregate record. Liqmeds Worldwide Limited's 20.8 average claims per patent is an average count, not a measure of claim scope, legal strength, enforceability, or design-around risk. The record spans 2 CPC subclasses. Combined with portfolio volume, these figures let readers compare the documented grant records of assignees in similar technology classes.
Who files at Liqmeds's volume?
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
- Leeo
Leeo, Inc.
28 patents
- Levitation Scienc…
Levitation Sciences LLC
28 patents
- Leybold
Leybold GmBH
28 patents
- Linamar
Linamar Corporation
28 patents
- Maersk OLIE OG GA…
MAERSK OLIE OG GAS A/S
28 patents
- Makinarocks
MAKINAROCKS CO., LTD.
28 patents
- Manitou BF
MANITOU BF
28 patents
- Matrixed Reality…
MATRIXED REALITY TECHNOLOGY CO., LTD.
28 patents
- Liqmeds Worldwide ◀
Liqmeds Worldwide Limited
28 patents
What this shows Liqmeds holds 28 patents at rank #10,988, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Companies ranked near Liqmeds
By rank, the assignees closest to #10,988 in granted patent volume.
- Leeo, Inc. #10,984 · 28 patents
- Levitation Sciences Llc #10,985 · 28 patents
- Leybold Gmbh #10,986 · 28 patents
- Linamar Corporation #10,987 · 28 patents
- Maersk OLIE OG GAS A/s #10,989 · 28 patents
- Makinarocks Co., Ltd. #10,990 · 28 patents
- Manitou BF #10,991 · 28 patents
- Matrixed Reality Technology Co., Ltd. #10,992 · 28 patents
Leaders in A61K (Preparations FOR Medical)
Other assignees with the most granted patents in Liqmeds's primary technology class.
- The Regents Of The University Of California 1,779 in class
- L'oreal 1,250 in class
- Novartis Ag 988 in class
- The Procter & Gamble Company 985 in class
- The Board Of Regents Of The University Of Texas System 950 in class
- The United States Of America, As Represented By The Secretary, Department Of Health And Human Services 813 in class
- The Trustees Of The University Of Pennsylvania 768 in class
- Merck Sharp & Dohme Llc 760 in class
Liqmeds's Innovation Score vs. every tracked assignee
Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)
49 Top 15% higher than 85% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2022–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2022 | 6 | 21.4% |
| 2023 | 4 | 14.3% |
| 2024 | 9 | 32.1% |
| 2025partial year | 9 | 32.1% |
Which technologies does Liqmeds Worldwide Limited patent most?
Top 2 of 2 technology areas
Grant record at a glance
Portfolio Volume 28 grants
CPC subclasses 2
Avg. claims / grant 20.8
Historical grant data only; it does not rate legal strength or current strategy.
Frequently Asked Questions
Where does Liqmeds Worldwide Limited rank among US patent assignees?
According to USPTO PatentsView (2015–2025 granted utility patents), Liqmeds Worldwide Limited ranks #10,988 of 50,000 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.
How many patents does Liqmeds Worldwide Limited hold?
Liqmeds Worldwide Limited holds 28 US utility patents granted between 2022 and 2025, spanning 2 technology areas.
What is Liqmeds Worldwide Limited's Innovation Score?
Liqmeds Worldwide Limited has an Innovation Score of 49.1 out of 100 (top 15% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does Liqmeds Worldwide Limited focus on?
Liqmeds Worldwide Limited's top technology area is A61K (PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES) with 28 patents. Grants appear in 2 CPC subclasses total.
Is Liqmeds Worldwide Limited's patent grant rate increasing or decreasing?
Insufficient historical data is available to calculate a velocity trend for Liqmeds Worldwide Limited.
What does claim depth mean for Liqmeds Worldwide Limited's patents?
Liqmeds Worldwide Limited's patents average 20.8 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.
How is the Liqmeds Worldwide Limited patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.
How to use this portfolio
Liqmeds's 28 grants land it in the top 15% by Innovation Score, but volume alone doesn't tell you where the strength sits.
- Read that count against the largest US assignees before treating it as dominance - Liqmeds ranks #10,988 of 50,000. Top 50 holders
- Most of this portfolio concentrates in A61K - see who else leads that technology area. A61K leaders
- Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.